Business Description
Novonesis (Novozymes) B
NAICS : 325411
ISIN : DK0060336014
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | 3.48 | |||||
Interest Coverage | 34.62 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.85 | |||||
Beneish M-Score | -1.03 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.1 | |||||
3-Year EBITDA Growth Rate | 4.7 | |||||
3-Year EPS without NRI Growth Rate | 7.4 | |||||
3-Year FCF Growth Rate | -14.6 | |||||
3-Year Book Growth Rate | 7.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | 11.82 | |||||
Future 3-5Y Total Revenue Growth Rate | 16.66 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.77 | |||||
9-Day RSI | 47.23 | |||||
14-Day RSI | 44.63 | |||||
6-1 Month Momentum % | 6.6 | |||||
12-1 Month Momentum % | 26.15 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.11 | |||||
Quick Ratio | 0.69 | |||||
Cash Ratio | 0.16 | |||||
Days Inventory | 184.73 | |||||
Days Sales Outstanding | 81.84 | |||||
Days Payable | 77.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.97 | |||||
Dividend Payout Ratio | 0.34 | |||||
3-Year Dividend Growth Rate | 25.1 | |||||
Forward Dividend Yield % | 1.98 | |||||
5-Year Yield-on-Cost % | 1.81 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | -2.04 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 54.32 | |||||
Operating Margin % | 24.94 | |||||
Net Margin % | 16.89 | |||||
FCF Margin % | 11.71 | |||||
ROE % | 9.78 | |||||
ROA % | 6.09 | |||||
ROIC % | 7.68 | |||||
ROC (Joel Greenblatt) % | 24.14 | |||||
ROCE % | 10.27 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 37.94 | |||||
Forward PE Ratio | 25.14 | |||||
PE Ratio without NRI | 33.88 | |||||
Price-to-Owner-Earnings | 211.07 | |||||
PEG Ratio | 8.07 | |||||
PS Ratio | 6.41 | |||||
PB Ratio | 2.34 | |||||
Price-to-Tangible-Book | 34.76 | |||||
Price-to-Free-Cash-Flow | 54.75 | |||||
Price-to-Operating-Cash-Flow | 27.64 | |||||
EV-to-EBIT | 47.98 | |||||
EV-to-Forward-EBIT | 27.46 | |||||
EV-to-EBITDA | 47.98 | |||||
EV-to-Forward-EBITDA | 20.48 | |||||
EV-to-Revenue | 11.43 | |||||
EV-to-Forward-Revenue | 6.44 | |||||
EV-to-FCF | 97.6 | |||||
Price-to-Projected-FCF | 2.17 | |||||
Price-to-DCF (Earnings Based) | 2.5 | |||||
Price-to-DCF (FCF Based) | 4.04 | |||||
Price-to-Median-PS-Value | 1.88 | |||||
Price-to-Graham-Number | 8.35 | |||||
Earnings Yield (Greenblatt) % | 2.08 | |||||
FCF Yield % | 1.09 | |||||
Forward Rate of Return (Yacktman) % | 3.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Novonesis (Novozymes) B Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 17,940.694 | ||
EPS (TTM) (kr) | 10.905 | ||
Beta | 0.66 | ||
Volatility % | 20.71 | ||
14-Day RSI | 44.63 | ||
14-Day ATR (kr) | 9.461544 | ||
20-Day SMA (kr) | 414.005 | ||
12-1 Month Momentum % | 26.15 | ||
52-Week Range (kr) | 343.9 - 485.9 | ||
Shares Outstanding (Mil) | 464.36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Novonesis (Novozymes) B Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Novonesis (Novozymes) B Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Novonesis (Novozymes) B Frequently Asked Questions
What is Novonesis (Novozymes) B(OCSE:NSIS B)'s stock price today?
When is next earnings date of Novonesis (Novozymes) B(OCSE:NSIS B)?
Does Novonesis (Novozymes) B(OCSE:NSIS B) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |